BioSpace News Archive

Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby monitoring system, for prescription use with healthy and sick babies 0-18 months of age.

ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic therapy to treat a range of solid tumors, announced the appointment of Eyal Morag, M.D., as Chief Medical Officer.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024.

Foundation for Sarcoidosis Research announces $100,000 in funding for support of research aimed at improving diagnosis, management, and treatment of cardiac sarcoidosis.

Annexon, Inc. announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

TFF Pharmaceuticals, Inc. announced that the Company will hold a conference call and webcast to review initial data from the ongoing Phase 2 trials of TFF VORI and TFF TAC on Tuesday, December 19th at 8:30 am ET.

Ocular Therapeutix™, Inc. announced the closing of its previously announced underwritten public offering of 35,420,000 shares of its common stock at a public offering price of $3.25 per share, which includes 4,620,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and CS.

CymaBay Therapeutics, Inc. announced the grant of inducement awards to four employees on December 15, 2023 in connection with the employees’ commencement of employment at CymaBay.

INmune Bio Inc. (NASDAQ: INMB) (the “Company”) is on track to complete enrollment of its Phase II clinical trial in patients with early Alzheimer’s Disease and biomarkers of inflammation in 2024.